I use quotetracker..I find it the best for daytrading..If you have an account with just about anyone,even TD Amer..It will work.
I'm shure there are a lot more "sinister goings on" and ready to be sprung on unsuspecting share holders..Oh the shame ,I'm buying more...Now this is a buying opp.!!
Inovio Pharmaceuticals, Inc. (NYSE:INO) is a biomedical company that focuses on the development of next-generation vaccines to prevent or treat cancers and chronic infectious diseases. Their DNA-based vaccines place a fragment of DNA in the body, which is expected to produce one or more targeted antigens, instead of creating an immunogen that, once placed in the body, should to induce a determined immune response. Once in the body’s cells, this “piece of DNA” gives instructions for them to produce the desired antigen. Thus, this type of vaccine induces strong, multi-faceted immune responses -similar to the response a body would have to actual pathogens- to provide future protection or eliminate infected cells.
These types of vaccines are administered by electroporation technology, meant to defeat cells´ natural resistance to the entry of foreign material. By creating temporary pores in the cell membrane with the use of controlled electrical pulses, electroporation allows the cellular uptake of the synthetic DNA vaccine previously injected into the body. This partnership now provides Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) with access to electroporation too.
In addition to the use of this technology, Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY) has purchased an exclusive license for Inovio Pharmaceuticals, Inc. (NYSE: INO)’s vaccines that target prostate cancer -the third and most common deadly type of cancer- and hepatitis B -an extremely infectious liver disease. Also, the Swiss company has acquired an option to license additional vaccine opportunities, in connection to the collaboration to further develop a research program in oncology.
Through this agreement Inovio Pharmaceuticals, Inc. (NYSE:INO) is entitled to receive up to two digits tiered royalties upon its product sales.
After a 15% stock price upsurge this Tuesday, it is likely that not much more will be heard about this partnership for a while. Despite electroporation has been proven viable, its place in the medicine of the future still relies on pending government regulatory approvals and licenses. Hence, although Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY)’s bet generates confidence in the firm, it will take some time before we can know for sure if Inovio Pharmaceuticals, Inc. (NYSE:INO)’s products can be fully developed and manufactured.
Unless they have a stupid reason not too!!
I think with the biggest bio tech in the world , Roche invested, you can sleep at nite..They wouldn't have bought in if it wasn't a done thing.Rouche has a lot of power .
Unlike biologic vaccines, Inovio's vaccines are comprised of computer-generated strands of synthetic DNA mixed with water. This works to give Inovio's product candidates a huge edge, as these synthetic therapies don't run the risk of producing the viruses which they aim to treat and can also be easily manufactured and stored at room temperature. Likewise, being that these vaccines are synthetic and not biologic has enabled Inovio to build a large IP and patent portfolio for its products. Currently the company's pipeline hosts over 400 patents and shows no sign of slowing its IP expansion. Specifically what Inovio has been patenting so aggressively thus far are its coded DNA sequences which are the foundational mechanism of action for its vaccines and therapies. Through these synthesized DNA transcription codes, Inovio's vaccines work to activate targeted immunological responses triggering the patient's own body to fight their disease more effectively. Along with the numerous published studies demonstrating the efficacy of the company's technology, recent pre-clinical data revealed that the company's hTERT DNA cancer vaccine generated a T-Cell immune system response 18-fold higher than the next best peer technology found in Merck's (MRK) DNA Plus Adenovirus Vector.
Let me tell you ,I've seen many times ,after good news,stocks not move until a day or two.Then the News starts to get digested and all of a sudden ,...bingo up it goes. I got a strong feeling we may see this unfold...It's a matter of digestion and ramifications of this last deal..but we will go up!
now who gave me thumbs down..I'm sitting here having a glass of home made wine and I have to see that..not good..
Cervical dysplasia HPV Type 16/18
Milestone: Phase II study enrollment completed; top-line data expected in mid-2014
Highlight: Phase I trial shows vaccine produces "killer T-cells" that kill cervical dysplasia cells
Roche Therapeutic Info:
Milestone: Initiate phase I/IIa 1H 2014
Highlight: Successful large animal results reinforce potential utility of Inovio's DNA vaccine approach for treating cancers
Milestone: Initiate phase I/IIa 2014
Milestone: Prepare phase I/IIa 2014
Hepatitis C Genotype 1a & 1b
NS3/4A, NS4B, NS5A
VGX International, Inc.
Milestone: Initiate phase I/IIa in HCV infected individuals in the fourth quarter of 2013
Highlight: Rhesus macaques mounted strong HCV-specific T cell immune responses strikingly similar to those reported in patients who have cleared the virus on their own.
HIV Clade B
gag, pol, env
HIV Vaccine Trials Network
Milestone: Data published in the Journal of Infectious Diseases in July 2013
Highlight: Significant vaccine-specific T-cell responses observed in 89% of phase I subjects
HIV Clades A, C, D
USMHRP/NIAID Preventive &
Milestone: Completed enrollment
Highlight: PENNVAX®-G plus MVA boost achieves 100% antigen-specific T-cell immune responses and safety with interim data
HIV Clades A, C (B)
gag, pol, env
NIH/NIAID/HVTN Preventive &
Milestone: Initiate phase I stud
I doubt Merck will allow the chair to be "kicked out from under neath it"..I think Merk of all is in the hot seat here,They can't sit back and let the spoils go to someone else?.Or do they get the jump or the rest of the field and buy the potential now to own the later product later...hummm